UNSPSC 51142547: Bromocriptine methanesulfonate

This classification denotes a neuroprotective agent with the molecular formula C32H40BrN5O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFP983J3OD, chemically known as ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'.alpha.)-, but more generally known as bromocriptine methanesulfonate, which bears US NIH Compound Identifier 31100.

European Medicines Agency schedules bromocriptine methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05918MIG. Most nations, for tariff purposes, schedule bromocriptine methanesulfonate under HS 29396900. SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6C7C(CCCC7[NH]C6BR)C5=C4)C)O.CS(=O)(=O)O.

UNSPSC 51142547 Bromocriptine methanesulfonate, a Commodity code, shows a mismatch between its nominal pharmaceutical scope and recent state and local solicitation activity. The single recent opportunity posted under this code is Seminole County, Florida's IFB 60459723LAS for Naloxone and Safe Drug Deactivation Systems—products unrelated to bromocriptine methanesulfonate. Seminole County's procurement seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract requires electronic bid submission, includes drug-free workplace certification and E-Verify compliance, carries an initial two-year term with a one-year renewal option, and features a three-month probationary termination clause. The procurement may be FEMA-funded and subjects contractors to federal environmental compliance requirements including the Clean Air Act and Federal Water Pollution Control Act.

The code shows minimal recent state and local activity grounded in its stated commodity definition. The single identified opportunity does not align with bromocriptine methanesulfonate procurement, suggesting either a tagging error in the underlying state and local sourcing data or very limited genuine demand for this pharmaceutical under this particular code in the recent procurement market. Vendors evaluating this code should verify current demand signals through direct inquiry with state health departments and county purchasing offices rather than relying on the posted opportunity, which appears mislabeled.